-The Hindu As it stands on the threshold of the Twelfth Plan, India has a historic opportunity to elevate education and healthcare as the strongest pillars of its future development. Yearning for life-building education is unprecedented today. Yet, as Amartya Sen pointed out last year, the system remains deeply unjust. Access to excellence is open to those who can afford it, while the less-affluent majority has been left behind without even...

In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker Bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by Bayer in India in 2008, is used in the treatment of...

-Reuters India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say.  On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug...

-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision.  The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...

In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat version of Bayer's patented anti-cancer drug, Nexavar, bringing down its price by 97%. In the first-ever case of compulsory licencing approval, the Indian Patent Office on Monday cleared the application of Hyderabad's Natco Pharma to sell generic drug Nexavar,...